Use Of Tafenoquine, Boceprevir Or Narlaprevir For Treating Infection Of SARS-COV-2 And Medical Composition Thereof

Abstract

The present disclosure relates to a method for preventing or inhibiting a synthesis of viral RNA of SARS-CoV-2 in a cell including contacting the cell with a sufficient concentration of tafenoquine, boceprevir or narlaprevir and a method for inhibiting an activity of a main protease (Mpro) of SARS-CoV-2 including contacting a SARS-CoV-2 with a sufficient concentration of tafenoquine, boceprevir or narlaprevir. A medical composition for use in a treatment of an infection of SARS-CoV-2 including a therapeutically effective amount of tafenoquine, boceprevir or narlaprevir is also provided.

Dependencies are inferred from the claim text.